Tailored timing of radioactive therapy may boost tumor control in NETs
NCT ID NCT05387603
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether personalizing the schedule of a radioactive drug (177Lu-DOTATOC) improves outcomes for people with advanced neuroendocrine tumors. About 300 participants will receive either a standard or personalized treatment plan, with some also taking capecitabine. The goal is to see if tailoring therapy extends the time before tumors grow again.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-DOTATOC (a radioactive drug) and capecitabine (a chemotherapy pill)
What this could lead to
If successful, this could show that personalizing the timing of radioactive therapy improves how long tumors stay controlled, with fewer side effects.
What could go wrong
This is a large phase 3 trial, but personalization may not significantly improve outcomes over standard care. Radioactive therapy carries risks like kidney damage and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Accademical Hospital, Uppsala, Dept. of Oncology
RECRUITINGUppsala, SE-752 37, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Karolinska University Hospital, Dept. of Oncology
RECRUITINGStockholm, SE-171 76, Sweden
Contact Phone: •••-•••-••••
Contact
-
Sahlgrenska University Hospital, Dept. of Oncology
RECRUITINGGothenburg, Sweden
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Skåne University Hospital, Dept. of Oncology
RECRUITINGLund, SE-226 52, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact